N-(N-isobutyryl-L-cysteinyl)-S-pivaloylcysteamine | 312304-41-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(N-isobutyryl-L-cysteinyl)-S-pivaloylcysteamine
• 英文别名: S-[2-[[(2R)-2-(2-methylpropanoylamino)-3-sulfanylpropanoyl]amino]ethyl] 2,2-dimethylpropanethioate
• CAS: 312304-41-9
• 化学式: C₁₄H₂₆N₂O₃S₂
• 分子量: 334.504
• InChiKey: BKKBPSBINYPFFO-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-(N-isobutyryl-S-trityl-L-cysteinyl)-S-pivaloylcysteamine 在 吡啶 、 silver nitrate 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 12.0h， 以70%的产率得到N-(N-isobutyryl-L-cysteinyl)-S-pivaloylcysteamine
  参考文献：
  名称：

  Synthesis of new N-isobutyryl-l-cysteine/MEA conjugates: Evaluation of their free radical-scavenging activities and anti-HIV properties in human macrophages

  摘要：

  Four novel N-isobutyryl-L-cysteine/2-mercaptoethylamine (MEA, cysteamine) conjugates have been designed and synthesized. The antioxidant activities of these new series were evaluated by three different free radical scavenging methods (DPPH test, ABTS test, and deoxyribose assay) and their metal binding capacity was evaluated by the ethidium bromide fluorescence binding assay. These results were compared with those obtained with their pro-GSH acetyl analogues recently developed in our laboratory. We observed that most of these compounds exhibit free radical-scavenging activities similar to those of Trolox, but always superior than NAC. While none of these new derivatives had pro-GSH activities, they displayed anti-HIV properties in human monocyte-derived macrophages infected in vitro. The present study demonstrates that these new N-isobutyryl derivatives, which are expected to have a greater bioavailability than their acetyl analogues, may have useful applications in HIV infection in respect to their antioxidant and anti-HIV activities. (C) 2008 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.bioorg.2008.02.001

文献信息

• Novel antioxidants, preparation processes and their uses
  申请人：——

  公开号：US20040158092A1

  公开（公告）日：2004-08-12

  The invention concerns a process for preparing compounds of general formula (I) 1 wherein R and R′ represent an alkyl radical or an aryl group; and R″ is hydrogen or a CO—R 1 group wherein R 1 is an alkyl radical or an aryl group; and wherein these compounds are or not in the thiazolidine form; by protecting the N-acyl-L-cysteine to form an intermediate compound; and then by coupling said intermediate compound with S-acylcysteamine hydrochloride or with thiazolidine.

  本发明涉及一种制备一般式（I）化合物的方法，其中R和R′代表烷基基团或芳基基团；R″为氢或CO—R1基团，其中R1为烷基基团或芳基基团；这些化合物是否处于噻唑烷形式；通过保护N-酰基-L-半胱氨酸形成中间化合物；然后通过与S-酰基半胱氨酸盐酸盐或噻唑烷耦合来制备所述中间化合物。
• Antioxidants, preparation processes and their uses
  申请人：Oiry Joel

  公开号：US06979747B2

  公开（公告）日：2005-12-27

  The invention concerns a process for preparing compounds of general formula (I) wherein R and R′ represent an alkyl radical or an aryl group; and R″ is hydrogen or a CO—R 1 group wherein R 1 is an alkyl radical or an aryl group; and wherein these compounds are or not in the thiazolidine form; by protecting the N-acyl-L-cysteine to form an intermediate compound; and then by coupling said intermediate compound with S-acylcysteamine hydrochloride or with thiazolidine.

  本发明涉及一种制备一般式（I）化合物的方法，其中R和R'代表烷基基团或芳基基团；而R"是氢或CO-R1基团，其中R1是烷基基团或芳基基团；这些化合物是否处于噻唑烷形式。该方法通过保护N-酰基-L-半胱氨酸形成中间化合物，然后通过与S-酰基半胱氨酸盐酸盐或噻唑烷偶联来制备所述中间化合物。
• US6979747B2
  申请人：——

  公开号：US6979747B2

  公开（公告）日：2005-12-27